

# CONFERENCE FINDINGS

**Ian Boulton**

**WHO/MMV Artemisinin Conference  
Mumbai, September 2009**

**TropMed Pharma  
Consulting**

# CAVEATS

- **Top line findings**
- **Personal**
- **Initial thoughts – no time for reflection**
- **Provoke comment**

# GUILIN - 2008

## Key themes:

- **Priorities: short-term vs long-term**
- **Communication, transparency, involvement**
- **Innovation**
- **Consensus**
- **Urgency**

# ONE YEAR LATER (1)

## Progress:

- **Yes – there has been progress!**
- **Innovations:**
  - **Funding (A2S2)**
  - **Initiatives (AMFm)**
  - **New technology (seeds, purification, yields, semi-synthetic, endoperoxides)**
- **Forecasts**
- **Communication, transparency, involvement**

# ONE YEAR LATER (2)


## Some Challenges Remain:

- **Forecasts**
- **Pricing – incentives through supply chain**
- **Market immaturity ⇒ uncertainties & risk**
- **Supply / Demand mismatch ⇒ risk of shortages**
- **Length of supply chain**
- **Importance of farmers**

# MEETING OBJECTIVES

- **Communication & updating:**
  - **Forecasting**
  - **ACT/API/artemisinin production**
    - **Quality standards**
    - **Innovations**
  - **Recent initiatives**
    - **AMFm**
    - **A2S2**
  - **External challenge - Resistance**
    - **Monotherapies**
    - **Counterfeit drugs**
- **Identify key challenges**
- **Priority actions for next 12 months**

# TENSIONS



**Going forward, we must be aware of and manage these tensions.**

# MUMBAI - 2009

## Key themes:

- **Priorities: short-term vs long-term**
- **Communication, transparency, involvement**
- **Innovation**
- **Consensus**
- **Urgency**

**Same as Guilin - 2008**



# PRIORITIES

- **Short-term:**
  - **Fill short-term supply gap (2010 – 12)**
  - **Finalise A2S2 funding scheme**
  - **Artemisinin monotherapies / resistance**
- **Long-term:**
  - **Smooth out supply to match demand**
  - **Long-term relations along supply chain**
    - **Reduce reliance on spot market**
  - **Improve production efficiencies**

# COMMUNICATION, TRANSPARENCY, INVOLVEMENT

- **Clarity on demand curves & potential supply shortfalls**
  - **Transparency of forecasting models**
- **Timing & impact of innovations & new initiatives**
- **Shared experiences**
- **Problem solving**

# INNOVATION

- **Improving current processes**
  - Growing, extraction, purification
- **Semi-synthetic production**  
*(post-2012)*
- **Synthetic endoperoxides**
- **Funding & improving access**
- **Quality standards**
- **Artemisinin monotherapy withdrawal**

# CONSENSUS

- **Importance of motivating farmers to ensure stable & adequate supply**
- **Need for long-term relations along supply chain**
- **Artemisinin monotherapy withdrawals**

# URGENCY

- Predicted shortages in 2010 – 12
- Increase area planted to meet forecast demand
- Innovations:-
  - Improve current processes
  - Shorten manufacturing lead times
- Artemisinin resistance & monotherapy withdrawal
- **Cannot meet demand ⇒ children will die**

# PRIORITY ACTIONS

- **Publication of forecasts**
- **Revisit price points for ACTs**
  - Adequate incentives throughout supply chain
  - Importance of motivating farmers
- **A2S2 design**
  - API manufacturer inclusion
- **Artemisinin monotherapy withdrawal**

# FINAL THOUGHTS

**Are we making progress?      Yes**

**Have we more to do?      Yes**

**THANK YOU**